StroMel™
Osteoarthritis of the knee
Phase 2Active
Key Facts
About Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profileTherapeutic Areas
Other Osteoarthritis of the knee Drugs
| Drug | Company | Phase |
|---|---|---|
| TG-C (Invossa) | Kolon TissueGene | Phase 3 |
| GNSC-001 | Genascence | Pre-clinical |
| XT-150 | Xalud Therapeutics | Phase 2b |